Trial reportPloS one2017
A double blind placebo controlled randomized trial of the effect of acute uric acid changes on inflammatory markers in humans: A pilot study.
Trial report in PloS one, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT01323335 (The Relationship Between Uric Acid and Inflammatory Markers), which is not on this map. Cited by 22 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
The Relationship Between Uric Acid and Inflammatory Markers
Who cites it
22 citing papers in PubMed, 28 citations in OpenAlex.
- Sex-sikpecific associations between serum uric acid and chronic rhinosinusitis: a retrospective case-control study.Frontiers in allergy · 2026Article
- Uric acid mediates the association of alpha-1 acid glycoprotein with gallstones in adult women in the United States.Scientific reports · 2025Article
- Downregulation of type I interferon signalling pathway by urate in primary human PBMCs.Immunology · 2025Article
- Epigenetic programming reshapes innate immune memory: decoding the molecular imprint of gouty inflammation.Frontiers in pharmacology · 2025Review
- Hyperuricemia-induced complications: dysfunctional macrophages serve as a potential bridge.Frontiers in immunology · 2025Review
- Associations between uric acid and depressive symptoms, and the mediating role of immunoinflammatory: Findings from rural older adults.Brain, behavior, & immunity - health · 2024Article
- Ethanol Extracts fromFoods (Basel, Switzerland) · 2024Article
- The Risk of COVID-19 and Its Outcomes in Korean Patients With Gout: A Multicenter, Retrospective, Observational Study.Journal of Korean medical science · 2024Observational
- Longitudinal changes in high sensitivity C-reactive protein associated with serum uric acid in the Korean Genome and Epidemiology Study.Scientific reports · 2024Article
- Integrating transcriptomics, eQTL, and Mendelian randomization to dissect monocyte roles in severe COVID-19 and gout flare.Frontiers in genetics · 2024Article
- Integration of network pharmacology and intestinal flora to investigate the mechanism of action of Chinese herbalPharmaceutical biology · 2022Article
- Recent progress and perspectives on the relationship between hyperuricemia and periodontitis.Frontiers in immunology · 2022Review
- Urate-induced epigenetic modifications in myeloid cells.Arthritis research & therapy · 2021Article
- [Exploring the therapeutic mechanism ofNan fang yi ke da xue xue bao = Journal of Southern Medical University · 2021Article
- Uric Acid Neuroprotection Associated to IL-6/STAT3 Signaling Pathway Activation in Rat Ischemic Stroke.Molecular neurobiology · 2021Article
- Urate-induced immune programming: Consequences for gouty arthritis and hyperuricemia.Immunological reviews · 2020Review
- Asymptomatic hyperuricaemia: a silent activator of the innate immune system.Nature reviews. Rheumatology · 2020Review
- Effects of a Low-Dose Spirulina/Turmeric Supplement on Cardiometabolic and Antioxidant Serum Markers of Patients With Abdominal Obesity.Frontiers in nutrition · 2020Article
- Effect ofMedicina (Kaunas, Lithuania) · 2019Article
- Hyperuricemia and Hypertension: Links and Risks.Integrated blood pressure control · 2019Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 3 institutions in 2 countries.
Funding
Abstract
Uric acid has been linked with increased risk of chronic disease such as cardiovascular disease and this association has been attributed to a pro-inflammatory effect. Indeed, observational studies have shown that high uric acid is associated with high level of pro-inflammatory cytokines in the blood. However, whether high uric acid directly affects inflammation or rather represents a parallel defensive antioxidant mechanism in response to pathology that causes inflammation is unknown. To determine whether acute increase or decrease uric acid levels affects inflammation in healthy individuals, a randomized, placebo-controlled, double blind clinical study of uric acid or rasburicase with 20 healthy volunteers in each treatment-placebo group was conducted at the National Institute on Aging (NIA) Clinical Research Unit (CRU) at Harbor Hospital in Baltimore, MD. Change in inflammatory response was assessed by administering an oral lipid tolerance before and after the treatment of uric acid, rasburicase and placebo. Following uric acid administration, there was an accentuated increase in IL-6 during the oral lipid tolerance test (P<0.001). No significant differences were observed after lowering of uric acid with rasburicase. No side effects were reported throughout the trial. In health individuals, acute increase in uric acid results in an increased IL-6 response when challenged with lipid load. Such effect of amplification of inflammatory response may explain the higher risk of chronic diseases observed in subclinical hyperuricemia in observational studies.
trial registrationClinicalTrials.gov NCT01323335.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.